Recombinant Human VEGFR2/KDR Fc Chimera Protein

Formulations:
Catalog # Availability Size / Price Qty
357-KD-050
Product Details
Citations (34)
FAQs
Reviews

Recombinant Human VEGFR2/KDR Fc Chimera Protein Summary

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-40 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.
Source
Mouse myeloma cell line, NS0-derived human VEGFR2/KDR/Flk-1 protein
Human VEGFR2
(Ala20-Glu764)
Accession # AAC16450
IEGRMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Ala20
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
110 kDa (monomer)
SDS-PAGE
160-170 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

357-KD

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

357-KD/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs
3791 (Human); 16542 (Mouse)
Alternate Names
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Citations for Recombinant Human VEGFR2/KDR Fc Chimera Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

34 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line
    Authors: H Seo, H Masuda, K Asagoshi, T Uchiki, S Kawata, G Sasaki, T Yabuki, S Miyai, N Takahashi, SI Hashimoto, A Sawada, A Takaiwa, C Koyama, K Tamai, K Kurosawa, KY Lin, K Ohta, Y Nakazaki
    Cell. Mol. Immunol., 2020;0(0):.
    Species: Mouse
    Sample Types:
  2. Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
    Authors: F Njau, N Shushakova, H Schenk, VC Wulfmeyer, R Bollin, J Menne, H Haller
    PLoS ONE, 2020;15(1):e0218494.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization
    Authors: Ö Uslu, J Herold, S M Kanse
    Cells, 2019;8(11):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  4. Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions
    Authors: JA Buczek-Tho, CB Rich, MA Nugent
    Int J Mol Sci, 2019;20(20):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  5. Enhancement of HIFU ablation by sonosensitizer-loading liquid fluorocarbon nanoparticles with pre-targeting in a mouse model
    Authors: Y Zhang, L Yong, Y Luo, X Ding, D Xu, X Gao, S Yan, Q Wang, J Luo, D Pu, J Zou
    Sci Rep, 2019;9(1):6982.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis
    Authors: CP Miller, C Tsuchida, Y Zheng, J Himmelfarb, S Akilesh
    Neoplasia, 2018;20(6):610-620.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models
    Authors: Y Li, JA Hickson, DJ Ambrosi, DL Haasch, KD Foster-Duk, LJ Eaton, EL Digiammari, SC Panchal, F Jiang, SR Mudd, C Zhang, SS Akella, W Gao, SL Ralston, L Naumovski, J Gu, SE Morgan-Lap
    Mol. Cancer Ther., 2018;0(0):.
    Applications: ELISA (Standard)
  8. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles
    Authors: J Wang, B Qin, X Chen, WR Wagner, FS Villanueva
    Mol. Pharm., 2017;14(3):781-790.
    Applications: Bioassay
  9. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics
    Authors: SB Mamer, S Chen, JC Weddell, A Palasz, A Wittenkell, M Kumar, PI Imoukhuede
    Sci Rep, 2017;7(1):16439.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  10. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy
    Authors: ME LeBlanc, W Wang, X Chen, NB Caberoy, F Guo, C Shen, Y Ji, H Tian, H Wang, R Chen, W Li
    J. Exp. Med, 2017;0(0):.
    Applications: Bioassay
  11. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis.
    Authors: Kyu-Yeon Han, Jin-Hong Chang, Hyun Lee, Dimitri T Azar
    Investigative Ophthalmology & Visual Science, 2016;0(0):1552-5783.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  12. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research
    Authors: Naoki Okada
    Mol Ther Oncolytics, 2016;3(0):16024.
    Species: Mouse
    Sample Types: Complex Sample Type
    Applications: Bioassay
  13. Differential receptor binding and regulatory mechanisms for the lymphangiogenic growth factors VEGF-C and VEGF-D
    Authors: Marc G Achen
    J. Biol. Chem., 2016;0(0):.
    Applications: Bioassay
  14. Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration
    Authors: Kun Ding
    MAbs, 2016;0(0):0.
    Applications: Bioassay
  15. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.
    Authors: Teran M, Nugent M
    J Biol Chem, 2015;290(26):16451-62.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  16. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.
    Authors: Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, Stahl S, Lofblom J
    Sci Rep, 2014;4(0):7518.
    Applications: Bioassay
  17. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
    Authors: Harris, Nicole C, Davydova, Natalia, Roufail, Sally, Paquet-Fifield, Sophie, Paavonen, Karri, Karnezis, Tara, Zhang, You-Fang, Sato, Teruhiko, Rothacker, Julie, Nice, Edouard, Stacker, Steven A, Achen, Marc G
    J Biol Chem, 2013;288(12):8176-86.
    Species: Human
    Sample Types: Protein
    Applications: Enzyme Assay
  18. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.
    Authors: Qi, Jian Hua, Ebrahem, Quteba, Ali, Mariya, Cutler, Alecia, Bell, Brent, Prayson, Nicholas, Sears, Jonathan, Knauper, Vera, Murphy, Gillian, Anand-Apte, Bela
    PLoS ONE, 2013;8(3):e55667.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Competitive ELISA
  19. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.
    Authors: Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A, Mongiat M
    Oncogene, 2012;31(26):3136-47.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  20. Vascular endothelial growth factor signals through platelet-derived growth factor receptor beta in meningiomas in vitro.
    Br. J. Cancer, 2012;107(10):1702-13.
    Species: N/A
    Sample Types: N/A
    Applications: TaqMan Protein Assay
  21. Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.
    Authors: Goyal A, Pal N, Concannon M, Paul M, Doran M, Poluzzi C, Sekiguchi K, Whitelock JM, Neill T, Iozzo RV
    J. Biol. Chem., 2011;286(29):25947-62.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Binding Assay
  22. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment.
    Authors: Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, Noel A, Foidart JM, Munaut C, Pequeux C
    FASEB J., 2010;24(10):3782-95.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  23. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.
    Authors: Nishiguchi KM, Kataoka K, Kachi S
    PLoS ONE, 2010;5(10):e13493.
    Species: Porcine
    Sample Types: Aqueous Humor
    Applications: Bioassay
  24. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
    Authors: Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ
    Br. J. Cancer, 2009;101(7):1183-93.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  25. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
    Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
    J. Biol. Chem., 2008;283(49):34250-9.
    Species: Synthetic
    Sample Types: Peptide
    Applications: Binding Assay
  26. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
    Authors: Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K
    J. Exp. Med., 2007;204(6):1431-40.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.
    Authors: Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ
    J. Biol. Chem., 2007;282(33):24049-56.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Binding Assay
  28. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes.
    Authors: Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM
    Nat. Med., 2007;13(4):504-9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  29. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1.
    Authors: Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D
    J. Biol. Chem., 2006;281(49):37844-52.
    Species: Human
    Sample Types: Buffer
    Applications: Bioassay
  30. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
    Authors: Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L
    Chem. Biol., 2006;13(5):549-56.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  31. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo.
    Authors: Ren WP, Markel DC, Zhang R, Peng X, Wu B, Monica H, Wooley PH
    Biomaterials, 2006;27(30):5161-9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  32. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.
    Authors: Seo KH, Lee HS, Jung B, Ko HM, Choi JH, Park SJ, Choi IH, Lee HK, Im SY
    Cancer Res., 2004;64(18):6482-8.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
    Authors: Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R
    Cancer Cell, 2004;6(5):507-16.
    Species: Human
    Sample Types:
    Applications: Functional ELISA
  34. Soluble CD54 induces human endothelial cells ex vivo expansion useful for cardiovascular regeneration and tissue engineering application.
    Authors: Malara N, Trunzo V, Musolino G, Aprigliano S, Rotta G, Macrina L, Limongi T, Gratteri S, Di Fabrizio E, Renzulli A, Fini M, Mollace V
    Int J Cardiol Heart Vasc, 0;6(0):48-53.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGFR2/KDR Fc Chimera Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGFR2/KDR Fc Chimera Protein and earn rewards!

Have you used Recombinant Human VEGFR2/KDR Fc Chimera Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review